Invitrogen™ Ezabenlimab Recombinant Monoclonal Antibody

Ezabenlimab, also known as BI 754091, is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1). The gene PDCD1, also known as PD-1 or CD279, encodes Programmed Cell Death Protein 1, a crucial immune checkpoint receptor expressed on T cells and other immune cells. Located on chromosome 2q37.3, PDCD1 consists of five exons. PD-1 is a type I transmembrane protein within the CD28/CTLA-4 superfamily and functions primarily to inhibit immune responses, thus maintaining peripheral tolerance and preventing autoimmune reactions. Upon binding to its ligands, PD-L1 and PD-L2, expressed on tumor cells and other tissues, PD-1 mediates the suppression of T-cell activity, inducing apoptosis in antigen-specific T cells while sparing regulatory T cells, contributing significantly to immune evasion by tumors.